The effect of aliskiren versus ramipril-based treatment on the ambulatory arterial stiffness index in hypertensive patients

International Angiology

Volumn 33, Issue 1, 2014, Pages 78-83

  Andreadis, E A ^a   Angelopoulos, E T ^a   Kolyvas, G N ^a   Agaliotis, G D ^a   Mousoulis, C G ^a   Mousoulis, G P ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Aliskiren; Hypertension; Vascular stiffness

Indexed keywords

ALISKIREN; AMLODIPINE; HYDROCHLOROTHIAZIDE; RAMIPRIL; AMIDE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUMARIC ACID DERIVATIVE; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADD ON THERAPY; ADULT; AMBULATORY ARTERIAL STIFFNESS INDEX; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; AGED; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; GREECE; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TIME; TREATMENT OUTCOME;

ADULT; AGED; AMIDES; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FUMARATES; GREECE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RAMIPRIL; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR STIFFNESS; VASODILATOR AGENTS;

EID: 84899047423     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laboux B et al. Aortic stiffness is an independent predictor of fetal stroke in essential hypertension. Stroke 2003;34:1203-6. (Pubitemid 36547514)
2. Kikuya M, Staessen JA, Ohkubo T, Thijs L, Metoki H, Asayama K et al. Ambulatory arterial stiffness index and 24-hour ambulatory pulse pressure as predictors of mortality in Ohasama Japan. Stroke 2007;38:1161-6. (Pubitemid 351664280)
3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
4. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindropril as required versus atenolol adding bench rofluethiazine as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906. (Pubitemid 41265663)
5. Andreadis EA, Sfakianakis ME, Tsourous GI, Georgiopoulos DX, Fragouli EG et al. Differential impact of angiotensin receptor blockers and calcium channel blockers on arterial stiffness. Int Angiol 2010;29:266-72.
6. Laurent S. Surrogate measures of arterial stiffness: do they have additive predictive value or are only surrogates of a surrogate? Hypertension 2006;47:327-8.
7. Li Y, Wang JG, Dolan E, Gao PJ, Guo HF, Nawrot T et al. Ambulatory arterial stiffness index derived from 24-h ambulatory blood pressure monitoring. Hypertension 2006;47:359-64. (Pubitemid 43740275)
8. Dolan E, Thijs L, Li Y, Atkings N, McCormack P, McClory S et al. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension 2006;47:365-70. (Pubitemid 43740276)
9. Jin Y, Thijs L, Richard T, Li Yan, Dolan E, Wang Ji-Guang et al., on behalf of the REASON Investigators. Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs. Hypertension Research 2011;34:489-495;doi:10.1038/hr.2010.256.
10. Kips JG, Vermeersch SJ, Philippe Reymond P, Boutouyrie P, Stergiopoulos N, Laurent S et al. Ambulatory arterial stiffness index does not accurately assess arterial stiffness. J Hypertens 2012;30:574-80.
11. Stergiou GS, Baibas NM, Gantzarou AP, Skeva II, Kalkana CB, Roussias LG et al. Reproducibility of home, ambulatory, and clinic blood pressure: implications for the design of trials for the assessment of antihypertensive drug efficacy. Am J Hypertens 2002;15:101-4. (Pubitemid 34161082)
12. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003;21:821-48. (Pubitemid 36677141)
13. Verdecchia P, Angeli F, Mazzotta G, Martire P, Garofoli M, Gentile G et al. Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis 2010;4:193-200.
14. The HOPE Investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
15. Dahlof B, Devereux R, de Faire U, Julius S, Beevers G, de Faire U et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study: A randomized trial against atenolol. Lancet 2002:995-1003. (Pubitemid 34286536)
16. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
17. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now and where are we going? J Hypertens 2006;24:243-56. (Pubitemid 43348229)
18. Westerhof N, Lanknaar JW, Westerhof BE. The ambulatory arterial stiffness index is not a stiffness parameter but a ventriculo-arterial coupling factor. Hypertension 2007;49:e7. (Pubitemid 46142989)
19. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27. (Pubitemid 34596167)